The next three years will be a proving period for Astellas. Its new Corporate Strategic Plan […]
Japan is genuinely interesting for companies developing cell therapies, gene therapies and regenerative medicine product. But […]
Japan’s ageing population is enormous. That does not automatically make Japan a good market for your […]
Daiichi Sankyo has built one of the pharmaceutical industry’s most productive antibody-drug conjugate platforms. Enhertu has […]
Large pharmaceutical targets often look like abstract financial noise to external vendors. But Otsuka’s target to […]
The biopharma world is still processing the seismic news of Isomorphic Labs’ $2.1 billion Series B […]
The Easy Hurdle That Kills Programs A drug candidate can clear the standard off-target panel and […]
Japan is no longer a market foreign medical device companies can afford to treat as “difficult […]
The High Stakes of Innovation: Balancing Takeda’s $1.26B ‘Launch Machine’ and a $2.5B Antitrust Hit as […]
Japan is one of the world’s most demanding healthcare markets. It is also one of the […]